• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血清 microRNA-371a-3p 水平在非生殖细胞来源的睾丸肿瘤中并未升高。

Serum levels of microRNA-371a-3p are not elevated in testicular tumours of non-germ cell origin.

机构信息

Faculty of Biology and Chemistry, University of Bremen, Bremen, Germany.

Department of Urology, Bundeswehrkrankenhaus Hamburg, Hamburg, Germany.

出版信息

J Cancer Res Clin Oncol. 2021 Feb;147(2):435-443. doi: 10.1007/s00432-020-03429-x. Epub 2020 Nov 16.

DOI:10.1007/s00432-020-03429-x
PMID:33200255
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7817581/
Abstract

PURPOSE

Serum levels of microRNA-371a-3p (M371) have been shown to be a highly sensitive and specific biomarker for testicular germ cell tumours (TGCT). Little information exists on the expression of this marker in testicular neoplasms deriving from the gonadal stroma or other structures of the gonad. This study presents an expression analysis of the novel TGCT-biomarker M371 in a large cohort of testicular non-germ cell tumours.

METHODS

The M371 expression was measured by quantitative real time PCR in serum of 99 patients with testicular tumours of non-germ cell origin, thereof 30 patients with malignant testicular lymphomas and 61 patients with gonadal stroma tumours such as Leydig cell tumours, Sertoli cell tumours and 8 cases with miscellaneous benign testicular tumours. Their M371 levels were compared to those of 20 patients with TGCT and to 37 tumour-free male controls.

RESULTS

The median expression levels of benign testicular tumours and testicular lymphoma are close to zero, thus, identical with those of controls and significantly lower than those of TGCT. In summary, this study provides further evidence for the notion that M371 is exclusively expressed by germ cell tumours and not by testicular neoplasms of the non-germ cell subtypes.

CONCLUSION

Clinically, the test might be of value in preoperative characterization of benign testicular tumours eligible for conservative surgery.

摘要

目的

已有研究表明,血清 microRNA-371a-3p(M371)水平是睾丸生殖细胞肿瘤(TGCT)的一种高度敏感和特异的生物标志物。然而,关于这种标志物在源自性腺基质或性腺其他结构的睾丸肿瘤中的表达情况,目前信息有限。本研究对大量非生殖细胞来源的睾丸肿瘤患者的新型 TGCT 生物标志物 M371 进行了表达分析。

方法

采用实时定量 PCR 法检测 99 例非生殖细胞来源的睾丸肿瘤患者(其中 30 例为恶性睾丸淋巴瘤患者,61 例为性腺基质肿瘤患者,如间质细胞瘤、支持细胞瘤,8 例为其他良性睾丸肿瘤患者)血清中的 M371 表达水平,并与 20 例 TGCT 患者和 37 例无肿瘤男性对照者的 M371 水平进行比较。

结果

良性睾丸肿瘤和睾丸淋巴瘤的中位数表达水平接近零,与对照组相同,且显著低于 TGCT。总之,本研究进一步证实了 M371 仅由生殖细胞肿瘤表达,而不由非生殖细胞亚型的睾丸肿瘤表达的观点。

结论

临床上,该检测方法可能有助于术前对适合保留手术的良性睾丸肿瘤进行特征描述。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cba1/11802068/1c04a661fa61/432_2020_3429_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cba1/11802068/5232b5335b6a/432_2020_3429_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cba1/11802068/e2071ea7a672/432_2020_3429_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cba1/11802068/1c04a661fa61/432_2020_3429_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cba1/11802068/5232b5335b6a/432_2020_3429_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cba1/11802068/e2071ea7a672/432_2020_3429_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cba1/11802068/1c04a661fa61/432_2020_3429_Fig3_HTML.jpg

相似文献

1
Serum levels of microRNA-371a-3p are not elevated in testicular tumours of non-germ cell origin.血清 microRNA-371a-3p 水平在非生殖细胞来源的睾丸肿瘤中并未升高。
J Cancer Res Clin Oncol. 2021 Feb;147(2):435-443. doi: 10.1007/s00432-020-03429-x. Epub 2020 Nov 16.
2
Testicular neoplasms: the interrelationships of serum levels of microRNA-371a-3p (M371) and classical tumor markers with histology, clinical staging, and age-a statistical analysis.睾丸肿瘤:血清 microRNA-371a-3p (M371) 水平与组织学、临床分期和年龄的经典肿瘤标志物之间的相互关系——一项统计学分析。
J Cancer Res Clin Oncol. 2023 Aug;149(10):7079-7090. doi: 10.1007/s00432-023-04664-8. Epub 2023 Mar 4.
3
NANOG controls testicular germ cell tumour stemness through regulation of MIR9-2.NANOG 通过调控 MIR9-2 来控制睾丸生殖细胞肿瘤干细胞特性。
Stem Cell Res Ther. 2024 May 1;15(1):128. doi: 10.1186/s13287-024-03724-1.
4
Biomarker microRNA-371a-3p - expression in malignancies other than germ-cell tumours.生物标志物微小RNA-371a-3p——在生殖细胞肿瘤以外的恶性肿瘤中的表达。
J Cancer Res Clin Oncol. 2025 Jan 31;151(2):58. doi: 10.1007/s00432-025-06101-4.
5
Serum Levels of MicroRNA-371a-3p for Predicting the Histology of Postchemotherapy Residual Masses of Germ Cell Tumours.血清 microRNA-371a-3p 水平预测生殖细胞肿瘤化疗后残留肿块的组织学特征。
Eur Urol Focus. 2024 Sep;10(5):851-857. doi: 10.1016/j.euf.2024.05.002. Epub 2024 May 9.
6
Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study.血清 microRNA-371a-3p(M371 检测)作为睾丸生殖细胞肿瘤的新型生物标志物:一项前瞻性多中心研究的结果。
J Clin Oncol. 2019 Jun 1;37(16):1412-1423. doi: 10.1200/JCO.18.01480. Epub 2019 Mar 15.
7
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.卡莫司汀植入剂与替莫唑胺治疗新诊断的高级别胶质瘤的有效性和成本效益:一项系统评价与经济学评估
Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450.
8
The Diagnostic Accuracy of miR-371a-3p for Testicular Germ Cell Tumors: A Systematic Review and Meta-Analysis.miR-371a-3p 对睾丸生殖细胞肿瘤的诊断准确性:系统评价和荟萃分析。
Mol Diagn Ther. 2021 May;25(3):273-281. doi: 10.1007/s40291-021-00521-x. Epub 2021 Apr 22.
9
Epigenetic silencing of the putative tumor suppressor gene testisin in testicular germ cell tumors.睾丸生殖细胞肿瘤中假定的肿瘤抑制基因testisin的表观遗传沉默。
J Cancer Res Clin Oncol. 2006 Dec;132(12):765-70. doi: 10.1007/s00432-006-0124-6. Epub 2006 Jun 21.
10
[Testicular Germ Cell Tumours - features and prospects of the novel tumour marker microRNA-371a-3p (M371 test): a narrative review].[睾丸生殖细胞肿瘤——新型肿瘤标志物微小RNA-371a-3p的特征与前景(M371检测):一篇叙述性综述]
Aktuelle Urol. 2024 Dec;55(6):510-519. doi: 10.1055/a-2358-8355. Epub 2024 Aug 12.

引用本文的文献

1
Prognostic gene expression and microRNA profiling signatures and genetic alterations in primary testicular diffuse large B-cell lymphoma.原发性睾丸弥漫性大B细胞淋巴瘤的预后基因表达、微小RNA谱特征及基因改变
Blood Cancer J. 2025 Jul 17;15(1):123. doi: 10.1038/s41408-025-01323-8.
2
Analysis of a mouse germ cell tumor model establishes pluripotency-associated miRNAs as conserved serum biomarkers for germ cell cancer detection.对小鼠生殖细胞肿瘤模型的分析确定了多能性相关的微小RNA作为用于生殖细胞癌检测的保守血清生物标志物。
Sci Rep. 2025 Feb 6;15(1):4452. doi: 10.1038/s41598-025-88554-8.
3
Biomarker microRNA-371a-3p - expression in malignancies other than germ-cell tumours.

本文引用的文献

1
Graded expression of microRNA-371a-3p in tumor tissues, contralateral testes, and in serum of patients with testicular germ cell tumor.微小RNA-371a-3p在睾丸生殖细胞肿瘤患者的肿瘤组织、对侧睾丸及血清中的分级表达。
Oncotarget. 2020 Apr 21;11(16):1462-1473. doi: 10.18632/oncotarget.27565.
2
Non-Coding microRNAs as Novel Potential Tumor Markers in Testicular Cancer.非编码微小RNA作为睾丸癌中新的潜在肿瘤标志物
Cancers (Basel). 2020 Mar 22;12(3):749. doi: 10.3390/cancers12030749.
3
Application of miRNAs in the diagnosis and monitoring of testicular germ cell tumours.
生物标志物微小RNA-371a-3p——在生殖细胞肿瘤以外的恶性肿瘤中的表达。
J Cancer Res Clin Oncol. 2025 Jan 31;151(2):58. doi: 10.1007/s00432-025-06101-4.
4
Prognostic gene expression and microRNA profiling signatures and genetic alterations in primary testicular diffuse large B-cell lymphoma.原发性睾丸弥漫性大B细胞淋巴瘤的预后基因表达、微小RNA谱特征及基因改变
Res Sq. 2025 Jan 6:rs.3.rs-5732026. doi: 10.21203/rs.3.rs-5732026/v1.
5
Potential next generation markers of testicular germ cell tumors: miRNA-371a-3p.睾丸生殖细胞肿瘤潜在的下一代标志物:miRNA-371a-3p。
Int Urol Nephrol. 2025 Mar;57(3):691-700. doi: 10.1007/s11255-024-04284-2. Epub 2024 Nov 22.
6
Perioperative Serum MicroRNA 371a-3p and 372-3p Levels in Patients with Clinically Localized Testicular Masses.临床局限性睾丸肿块患者围手术期血清微小RNA 371a - 3p和372 - 3p水平
Eur Urol Open Sci. 2024 Aug 17;68:1-9. doi: 10.1016/j.euros.2024.08.003. eCollection 2024 Oct.
7
Advancing GCT Management: A Review of miR-371a-3p and Other miRNAs in Comparison to Traditional Serum Tumor Markers.进展期生殖细胞肿瘤管理:与传统血清肿瘤标志物相比,miR-371a-3p及其他微小RNA的综述
Cancers (Basel). 2024 Mar 31;16(7):1379. doi: 10.3390/cancers16071379.
8
Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study.通过 DRKS-00019223 研究中对 I 期睾丸生殖细胞肿瘤的随访,通过血清 microRNA-371a-3p 水平检测复发。
Clin Cancer Res. 2024 Jan 17;30(2):404-412. doi: 10.1158/1078-0432.CCR-23-0730.
9
Testicular neoplasms: the interrelationships of serum levels of microRNA-371a-3p (M371) and classical tumor markers with histology, clinical staging, and age-a statistical analysis.睾丸肿瘤:血清 microRNA-371a-3p (M371) 水平与组织学、临床分期和年龄的经典肿瘤标志物之间的相互关系——一项统计学分析。
J Cancer Res Clin Oncol. 2023 Aug;149(10):7079-7090. doi: 10.1007/s00432-023-04664-8. Epub 2023 Mar 4.
10
DigiMir Test: Establishing a Novel Pipeline for MiR-371a Quantification Using Droplet Digital PCR in Liquid Biopsies From Testicular Germ Cell Tumor Patients.数字微滴式逆转录聚合酶链反应检测:利用液滴数字PCR在睾丸生殖细胞肿瘤患者的液体活检中建立一种用于定量检测miR-371a的新型流程。
Front Oncol. 2022 Jun 10;12:876732. doi: 10.3389/fonc.2022.876732. eCollection 2022.
miRNAs 在睾丸生殖细胞肿瘤的诊断和监测中的应用。
Nat Rev Urol. 2020 Apr;17(4):201-213. doi: 10.1038/s41585-020-0296-x. Epub 2020 Mar 10.
4
Leydig-cell tumour of the testis: retrospective analysis of clinical and therapeutic features in 204 cases.睾丸间质细胞瘤:204 例临床和治疗特征的回顾性分析。
World J Urol. 2020 Nov;38(11):2857-2862. doi: 10.1007/s00345-020-03079-1. Epub 2020 Jan 20.
5
Rare benign and malignant testicular lesions: histopathology and management.罕见的良性和恶性睾丸病变:组织病理学和处理。
Curr Opin Urol. 2020 Mar;30(2):235-244. doi: 10.1097/MOU.0000000000000715.
6
MicroRNAs as Appropriate Discriminators in Non-Specific Alpha-Fetoprotein (AFP) Elevation in Testicular Germ Cell Tumor Patients.微小RNA作为睾丸生殖细胞肿瘤患者非特异性甲胎蛋白(AFP)升高的合适鉴别指标
Noncoding RNA. 2020 Jan 1;6(1):2. doi: 10.3390/ncrna6010002.
7
Risk Factors and Treatment Outcomes of 1,375 Patients with Testicular Leydig Cell Tumors: Analysis of Published Case Series Data.1375 例睾丸间质细胞瘤患者的风险因素和治疗结果:已发表病例系列数据分析。
J Urol. 2020 May;203(5):949-956. doi: 10.1097/JU.0000000000000705. Epub 2019 Dec 17.
8
Testis Sparing Surgery of Small Testicular Masses: Retrospective Analysis of a Multicenter Cohort.保留睾丸的小睾丸肿块手术:多中心队列的回顾性分析。
J Urol. 2020 Apr;203(4):760-766. doi: 10.1097/JU.0000000000000579. Epub 2019 Oct 3.
9
Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study.血清 microRNA-371a-3p(M371 检测)作为睾丸生殖细胞肿瘤的新型生物标志物:一项前瞻性多中心研究的结果。
J Clin Oncol. 2019 Jun 1;37(16):1412-1423. doi: 10.1200/JCO.18.01480. Epub 2019 Mar 15.
10
Human Germ Cell Tumors are Developmental Cancers: Impact of Epigenetics on Pathobiology and Clinic.人类生殖细胞肿瘤是发育性癌症:表观遗传学对病理生物学和临床的影响。
Int J Mol Sci. 2019 Jan 10;20(2):258. doi: 10.3390/ijms20020258.